IPHA – innate pharma s.a. - american depositary shares (US:NASDAQ)

News

Innate Pharma S.A. (NASDAQ: IPHA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $11.50 price target on the stock.
Innate Pharma Highlights Abstracts Selected for EHA 2024 Congress [Yahoo! Finance]
Innate Pharma Highlights Abstracts Selected for EHA 2024 Congress
Innate Pharma Reports First Quarter 2024 Business Update and Financial Results [Yahoo! Finance]
Innate Pharma Reports First Quarter 2024 Business Update and Financial Results
Show more
Live Event: Join our next subscriber-only event: "The Data Driven Investor"
Register for our next upcoming LIVE training session, which will be hosted on Tuesday April 24th at 08:00 PM EST (New York Time).
Get your questions answered during the Q & A session.
For any support questions, contact our team: support@newsquantified.com